Apixaban may be more effective and safer than rivaroxaban, research suggests
Research suggests that taking apixaban for non-valvular atrial fibrillation may be more effective and safer than taking rivaroxaban.
Source: Dr P Marazzi / Science Photo Library
Adults with non-valvular atrial fibrillation prescribed apixaban have a lower rate of ischaemic stroke and systemic blood clots compared with those prescribed rivaroxaban, according to a retrospective cohort study in Annals of Internal Medicine (10 March 2020).
People taking apixaban were also less likely to experience gastro-intestinal bleeding or bleeding in the brain.
Researchers studied a US insurance claims database to compare the safety and effectiveness of apixaban versus rivaroxaban for more than 78,000 patients with non-valvular atrial fibrillation.
After 290 days of follow-up, the rate of ischaemic stroke or systemic embolism was 6.6 per 1,000 person-years for adults prescribed apixaban, compared with 8.0 per 1,000 person-years for those prescribed rivaroxaban (hazard ratio [HR] 0.82; 95% confidence interval [CI] 0.68–0.98).
The apixaban group also had a lower rate of gastrointestinal bleeding or intracranial haemorrhage compared with those prescribed rivaroxaban (12.9 vs. 21.9 per 1,000 person-years; HR 0.58; 95% CI 0.52–0.66).
The researchers, led by Michael Fralick, a pharmacoepidemiology and pharmacoeconomics research fellow at the Brigham and Women’s Hospital in Boston, Massachusetts, wrote: “Until head-to-head clinical trial data are available, the results of our study … [provide] updated evidence in support of apixaban for treating non-valvular atrial fibrillation.”
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20207924
Recommended from Pharmaceutical Press
The new edition of Conducting Your Pharmacy Practice Research Project looks the stages of the research process in logical order, from planning of the project through to dissemination of the findings.£30.00Buy now